Quantbot Technologies LP Has $336,000 Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Quantbot Technologies LP lowered its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 60.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,650 shares of the medical instruments supplier’s stock after selling 5,550 shares during the period. Quantbot Technologies LP’s holdings in LeMaitre Vascular were worth $336,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LMAT. Smartleaf Asset Management LLC lifted its stake in shares of LeMaitre Vascular by 234.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC increased its holdings in LeMaitre Vascular by 38.5% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 117 shares in the last quarter. KBC Group NV increased its holdings in LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 410 shares in the last quarter. Empowered Funds LLC bought a new position in LeMaitre Vascular in the fourth quarter valued at about $150,000. Finally, SG Americas Securities LLC acquired a new stake in shares of LeMaitre Vascular during the fourth quarter valued at about $158,000. Institutional investors own 84.64% of the company’s stock.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the transaction, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. This represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $83.05 on Friday. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of 45.38, a PEG ratio of 2.22 and a beta of 0.89. The stock’s 50-day moving average is $93.07 and its 200 day moving average is $94.31. LeMaitre Vascular, Inc. has a one year low of $62.39 and a one year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. On average, sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, March 13th. This represents a $0.80 annualized dividend and a dividend yield of 0.96%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio is currently 41.24%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on LMAT. Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Lake Street Capital increased their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday, February 28th. Finally, Wells Fargo & Company started coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $95.25.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.